Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults

Show simple item record

dc.contributor.author Gorse, G.J.
dc.contributor.author Baden, L.R.
dc.contributor.author Wecker, M.
dc.contributor.author Newman, M.J.
dc.contributor.author Ferrari, G.
dc.contributor.author Weinhold, K.J.
dc.contributor.author Livingston, B.D.
dc.contributor.author Villafana, T.L.
dc.contributor.author Li, H.
dc.contributor.author Noonan, E.
dc.contributor.author Russell, N.D.
dc.date.accessioned 2012-12-31T14:07:21Z
dc.date.accessioned 2017-10-19T12:11:36Z
dc.date.available 2012-12-31T14:07:21Z
dc.date.available 2017-10-19T12:11:36Z
dc.date.issued 2008
dc.identifier.citation 26(2):215-23 en_US
dc.identifier.uri http://197.255.68.203/handle/123456789/2076
dc.description.abstract We evaluated EP HIV-1090 vaccine, a DNA plasmid encoding 21 cytotoxic T-lymphocyte (CTL) epitopes of human immunodeficiency virus type 1 (HIV-1) and the pan-DR helper T-lymphocyte epitope (PADRE), in a dose escalation, randomized, double-blinded, placebo-controlled Phase 1 trial. Vaccine, at 0.5, 2.0, or 4.0mg doses, or placebo was injected four times over 6 months. Forty-two healthy, HIV-1-uninfected adults were enrolled. Using an interferon-gamma ELISPOT assay, a response to PADRE was detected in one vaccine recipient. Three vaccine recipients raised anti-HIV-1 CD8+ CTL measured by chromium-release assay. The vaccine was safe and well-tolerated, but only weakly immunogenic. en_US
dc.language.iso en en_US
dc.publisher Vaccine Journal en_US
dc.title Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults en_US
dc.type Article en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search UGSpace


Browse

My Account